Document Type : Original Article
- Omid Mirmosayyeb 1
- Vahid Shaygannejad 2
- Mahshad Afsharzadeh 3
- Roozbeh Bataei 3
- Nasim Nehzat 3
- Aida Mohammadi 4
- Mahsa Ghajarzadeh 4
1 Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran Universal Council of Epidemiology, Universal Scientific Education and Research Network, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
3 Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
4 Universal Council of Epidemiology, Universal Scientific Education and Research Network, Tehran University of Medical Sciences, Tehran, Iran
Background: The purpose of this study was to evaluate the validity and reliability of the Persian version of Patient Determined Disease Steps (PDDS) in both patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD).
Methods: One hundred and forty-five patients were enrolled between May and September 2020 by consecutive sampling. Participants were asked to complete timed 25-foot walk (T25FW), 12-item Multiple Sclerosis Walking Scale (MSWS-12), and Multiple Sclerosis Quality of Life-54 (MSQOL-54). Patients also completed Timed Up and Go (TUG) and six-minute walk (6MW) tests. Construct validity was assessed by calculating correlation between PDDS and ambulatory and demographic items. The intra-class correlation coefficient (ICC) was used to evaluate reliability.
Results: One hundred and eleven patients with MS and 34 with NMOSD with disease duration of 7.6 ± 5.8 years were enrolled. Twenty-seven percent were men and mean Expanded Disability Status Scale (EDSS) was 1.8 ± 1.8.
There was a significant positive correlation between EDSS and PDSS (rho = 0.64, P < 0.001) which was evident in MS subgroups and NMOSD [secondary progressive MS (SPMS): rho = 0.64, P < 0.001; relapsing-remitting MS (RRMS): rho = 0.47, P < 0.001; NMOSD: rho = 0.52, P = 0.001]. PDDS had also significant positive correlation with TUG, T25FW, and MSWS-12. PDDS had also significant negative correlation with 6MW test. PDDS had weak correlation with demographic variables. The ICC was calculated as 0.99 for PDDS.
Conclusion: The Persian version of PDDS provides valid and reliable instrument to assess MS/NMOSD-related disability.
- Ghajarzadeh M, Jalilian R, Eskandari G, Sahraian MA, Azimi ARS. Validity and reliability of Persian version of Modified Fatigue Impact Scale (MFIS) questionnaire in Iranian patients with multiple sclerosis. Disabil Rehabil 2013; 35(18): 1509-12.
- Mirmosayyeb O, Brand S, Barzegar M, Afshari-Safavi A, Nehzat N, Shaygannejad V, et al. Clinical characteristics and disability progression of early- and late-onset multiple sclerosis compared to adult-onset multiple sclerosis. J Clin Med 2020; 9(5): 1326.
- Larocca NG. Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners. Patient 2011; 4(3): 189-201.
- Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444-52.
- Learmonth YC, Motl RW, Sandroff BM, Pula JH, Cadavid D. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol 2013; 13: 37.
- Marrie RA, Goldman M. Validity of performance scales for disability assessment in multiple sclerosis. Mult Scler 2007; 13(9): 1176-82.
- Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004; 10(5): 589-95.
- Lo AC, Hadjimichael O, Vollmer TL. Treatment patterns of multiple sclerosis patients: A comparison of veterans and non-veterans using the NARCOMS registry. Mult Scler 2005; 11(1): 33-40.
- Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: A cross-sectional study in the United States. Neurology 2006; 66(11): 1696-702.
- Hadjimichael O, Kerns RD, Rizzo MA, Cutter G, Vollmer T. Persistent pain and uncomfortable sensations in persons with multiple sclerosis. Pain 2007; 127(1-2): 35-41.
- Motl RW, Dlugonski D, Suh Y, Weikert M, Fernhall B, Goldman M. Accelerometry and its association with objective markers of walking limitations in ambulatory adults with multiple sclerosis. Arch Phys Med Rehabil 2010; 91(12): 1942-7.
- Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): An integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999; 5(4): 244-50.
- Nakhostin Ansari N, Naghdi S, Mohammadi R, Hasson S. Multiple Sclerosis Walking Scale-12, translation, adaptation and validation for the Persian language population. Gait Posture 2015; 41(2): 420-4.
- Nilsagard Y, Lundholm C, Gunnarsson LG, Dcnison E. Clinical relevance using timed walk tests and 'timed up and go' testing in persons with multiple sclerosis. Physiother Res Int 2007; 12(2): 105-14.
- Aslankhani MA, Farsi A, Fathirezaie Z, Zamani Sani SH, Aghdasi MT. Validity and reliability of the Timed Up and Go and the Anterior Functional Reach Tests in Evaluating Fall Risk in the Elderly. Salmand Iran J Ageing 2015; 10(1): 16-25. [In Persian].
- Goldman MD, Marrie RA, Cohen JA. Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler 2008; 14(3): 383-90.
- Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology 2003; 60(1): 31-6.
- Ghaem H, Borhani HA, Jafari P, Nikseresht AR. Validity and reliability of the Persian version of the multiple sclerosis quality of life questionnaire. Neurol India 2007; 55(4): 369-75.
- Kahraman T, Ozdogar AT, Ozakbas S. Cross-cultural adaptation, validity and reliability of the Turkish version of the patient determined disease steps scale in persons with multiple sclerosis. Physiother Theory Pract 2021; 37(4): 527-34.
- Lavorgna L, Sparaco M, Esposito S, Motl RW, Gallo A, Bisecco A, et al. Validity and reproducibility of the Italian version of the patient determined disease steps scale in people with multiple sclerosis. Mult Scler Relat Disord 2017; 18: 173-6.
- Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: A simple approach to evaluate disease progression. Neurology 1995; 45(2): 251-5.
- Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol 2014; 14: 58.